Perjeta (pertuzumab) | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

686 results for “Perjeta (pertuzumab)”

Trials

View all 542 →

A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer

95 participants · First posted Aug 28, 2012

Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects

160 participants · First posted Jun 2, 2020

HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy

135 participants · First posted Jan 29, 2013

Drugs

View all 48 →

Pertuzumab(Perjeta, Perjeta-Herceptin, Phesgo)

Manufacturer: Hoffmann-La Roche Limited

Conditions: Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC) +3 more

89Zr-pertuzumab

Pertuzumab zuvotolimod

News

View all 96 →

Henlius and Organon's HLX11 Biosimilar Meets Primary Endpoint in Phase 3 Breast Cancer Trial

FDA Approves First Perjeta Biosimilar as Shanghai Henlius and Organon Secure Interchangeable Status

EMA Committee Backs Roche's Phesgo, A Novel Subcutaneous Combination of Herceptin and Perjeta for HER2+ Breast Cancer

Page 1 of 69